Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK0974 tablet
MK0974 · 3 trials · 1 indication
Pain Freedom was defined as a reduction of a Grade 2 or 3 severity migraine at baseline to a no pain (Grade 0) at 2 hours post dose. Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.
Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours post dose. Headache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.
Respective experience (yes/no) of migraine-associated symptoms (including photophobia) was recorded by the patient in a diary.
Respective experience (yes/no) of migraine-associated symptoms (including phonophobia) was recorded by the patient in a diary.
Respective experience (yes/no) of migraine-associated symptoms (including nausea) was recorded by the patient in a diary.
Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), 3 (severe). Pain Relief is defined as participants reporting relief from moderate to severe migraine headache (Grade 2 or 3) to mild or none (Grade 1 or 0) in the setting of a typical migraine attack.
| Arm | Type | Description |
|---|---|---|
| MK0974 50 mg | EXPERIMENTAL | MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack |
| MK0974 150 mg | EXPERIMENTAL | MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack |
| MK0974 300 mg | EXPERIMENTAL | MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack |
| Placebo | PLACEBO_COMPARATOR | Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack |
| MK0974 25 mg | EXPERIMENTAL | MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache. |
| MK0974 100 mg | EXPERIMENTAL | MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache. |
| MK0974 200 mg | EXPERIMENTAL | MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache. |
| MK0974 400 mg | EXPERIMENTAL | MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache. |
| MK0974 600 mg | EXPERIMENTAL | MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache. |
| Rizatriptan 10 mg | ACTIVE_COMPARATOR | Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache. |
| 1 | EXPERIMENTAL | MK0974 Tablet |
| 2 | ACTIVE_COMPARATOR | MK0974 Liquid filled capsule |
| Name | Type | Description |
|---|---|---|
| MK0974 50 mg | DRUG | - |
| MK0974 150 mg | DRUG | - |
| MK0974 300 mg | DRUG | - |
| Comparator: Placebo | DRUG | MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo. |
| MK0974 | DRUG | MK0974 25 mg; one orally-administered dose |
| Rizatriptan | DRUG | Rizatriptan 10 mg; one orally-administered dose |
| MK0974 tablet | DRUG | MK0974 280 mg tablet in one of two treatment periods |
| Comparator: MK0974 liquid filled capsule | DRUG | MK0974 300 mg liquid filled capsule in one of two treatment periods |
Inclusion Criteria: * Patient has at least 1 year history of migraine (with or without aura) * Females of childbearing years must use acceptable contraception throughout trial Exclusion Criteria: * Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period) *...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
MK0974 is an investigational small molecule being studied for the treatment of migraine. It has been evaluated in clinical trials for acute migraine, meaning treatment taken during a migraine attack. It is in Phase 3 development and is not described as approved for any indication.
MK0974 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the clinical trial program for the drug, including Phase 1, Phase 2, and Phase 3 studies in migraine.
MK0974 is in Phase 3 development. Its clinical program includes a completed Phase 3 safety and efficacy study, a completed Phase 2 dose-finding study, and a completed Phase 1 bioequivalence study. All three trials are listed as completed, with no active trials.
MK0974 has been studied in three completed trials: NCT00432237, a Phase 3 safety and efficacy study in acute migraine with 1,703 participants; NCT00246337, a Phase 2 dose-finding study in acute migraine with 420 participants; and NCT00966030, a Phase 1 bioequivalence study comparing tablet and liquid-filled capsule forms with 50 healthy volunteers.
Across the three completed MK0974 trials, 2,173 participants were enrolled in total. The largest was the Phase 3 study NCT00432237 with 1,703 participants, followed by the Phase 2 dose-finding study NCT00246337 with 420 participants and the Phase 1 bioequivalence study NCT00966030 with 50 healthy volunteers.